Integra LifeSciences (NSDQ:IART) today posted second-quarter results that beat the overall consensus on Wall Street.
The Princeton, N.J.-based company reported profits of $35.1 million, to 41¢ per share, on sales of $389.9 million, for the three months ended June 30, for a sales growth of 50.8% compared with Q2 2020.
Earnings per share were 79¢, 13¢ ahead of The Street, where analysts were looking for sales of $376 million.
“We are pleased with second-quarter results that exceeded our forecasts. Our business segments were well-positioned to capitalize on the improving demand driven by the ongoing global market recovery,” president and CEO Peter Arduini said in a news release.
“We saw particularly healthy order activity in products used in neurosurgery, instruments, burn, trauma and surgical reconstruction as markets gradually recovered. Areas such as capital equipment and our international indirect markets are still early in their recovery but are reporting encouraging trends. As a result of our better than expected second-quarter financial performance, we are raising our full-year revenue and EPS guidance.”
Integra Lifesciences is raising its full-year 2021 outlook by $15 million to a range of $1.540 billion to $1.550 billion. It is also raising its full-year 2021 adjusted earnings per share guidance to a new range of $2.98 to $3.05.
Shares in IART were at a standstill this morning at $71.20 apiece.